{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T17:24:57Z","timestamp":1708622697049},"reference-count":23,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,7,20]],"date-time":"2006-07-20T00:00:00Z","timestamp":1153353600000},"content-version":"vor","delay-in-days":6409,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Pediatr. Oncol."],"published-print":{"date-parts":[[1989,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Between 1976 and 1986, 2,093 children with ALL were enrolled in three consecutive generations of trials conducted by the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). A 50% event\u2010free survival at 5 years was achieved overall in this population, approximately accounting for more than 50% of the entire childhood ALL population in Italy. Participation in the group protocols increased from the original seven founding centers to the current 37 institutions. Results in the standard population (non\u2010T immunophenotype, non\u2010FAB L3, and &lt; 50,000 white blood cells [WBC]\/ml) were considerably better with more recent, more aggressive protocols. The two major results in this population (N = 540) were a relatively low incidence (8% at 5 years) of central nervous system (CNS) relapse in the \u201cgood\u201d\u2010risk population (&lt; 10,000 WBC, ages 3\u20136 years, and FAB L1), without the use of cranial irradiation, and a projected 4\u2010year disease\u2010free interval for bone\u2010marrow relapse of 80% in the \u201caverage\u201d\u2010risk group, where a three\u2010drug reinduction program was adopted after consolidation. Overall, the event\u2010free survival of the most recent generation (protocol 82, median follow\u2010up time of 38 months) is 66% at 4 years (95% confidence limits [CL] 61\u201371). Based on these 10 years of experience, the general strategy of the group for the 90s is outlined and discussed.<\/jats:p>","DOI":"10.1002\/mpo.2950170203","type":"journal-article","created":{"date-parts":[[2007,2,20]],"date-time":"2007-02-20T17:44:31Z","timestamp":1171993471000},"page":"83-91","source":"Crossref","is-referenced-by-count":39,"title":["Treating childhood acute lymphoblastic leukaemia (ALL): Summary of ten years' experience in Italy"],"prefix":"10.1002","volume":"17","author":[{"given":"G.","family":"Paolucci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Masera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Vecchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Marsoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pession","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. G.","family":"Zurlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,20]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197202)29:2<381::AID-CNCR2820290219>3.0.CO;2-P"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V56.1.1.1"},{"key":"e_1_2_1_4_2","first-page":"159","volume-title":"Recent Results in Cancer Research","author":"Lampert F","year":"1984"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2964(81)90017-7"},{"key":"e_1_2_1_6_2","first-page":"119","article-title":"A cooperative study on the therapy of acute lymphoblastic leukemia. Results of the Italian Association Against Leukemia","volume":"64","author":"Italian Association Against Leukemia (AIL)","year":"1979","journal-title":"Haematologica"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19860301)57:5<1052::AID-CNCR2820570530>3.0.CO;2-0"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(87)90309-9"},{"key":"e_1_2_1_9_2","unstructured":"LiatiP MarsoniS ZurloMG et al.:Quality control (QC) of treatment of childhood acute lymphoblastic leukemia (ALL) in a pediatric cooperative group. In \u201c4th International Symposium on Therapy of Acute Leukemias \u201d Rome 7\u201312 February1987 p.169(Abstract 67)."},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950140317"},{"key":"e_1_2_1_11_2","unstructured":"Associazione Italiana Ematologia Oncologia Pediatrica: Bollettino n.3. Immuno SpA Pisa 1980."},{"key":"e_1_2_1_12_2","unstructured":"Associazione Italiana Ematologia Oncologia Pediatrica. Bollettino n.4. Immuno SpA Pisa 1982."},{"key":"e_1_2_1_13_2","volume-title":"Statistical Methods for Rates and Proportions","author":"Fleiss JL","year":"1973"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21979"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/64.1.156"},{"key":"e_1_2_1_16_2","first-page":"131","article-title":"Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries","volume":"12","author":"Bleyer WA","year":"1985","journal-title":"Sem. Oncol."},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1159\/000226540"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19830315)51:6<1041::AID-CNCR2820510612>3.0.CO;2-G"},{"key":"e_1_2_1_19_2","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1200\/JCO.1986.4.5.744","article-title":"Improved disease free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York Regimen\u2014A new intensive therapy protocol: A report from the CCSG","volume":"4","author":"Steinherz PG","year":"1986","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1026780"},{"key":"e_1_2_1_21_2","first-page":"162","article-title":"Superiority of intensive therapy for children with previously untreated acute lymphoblastic leukemia (ALL) and unfavourable prognostic features (UPF) (abstract 634)","volume":"5","author":"Gaynon P","year":"1986","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198609113151101"},{"key":"e_1_2_1_23_2","unstructured":"CamittaB LauerS CasperJ:Early intensive rotating therapy for higher risk childhood acute lymphocytic leukemia (CALL). In \u201c4th International Symposium on Therapy of Acute Leukemias \u201d Rome 7\u201312 February1987 p187(Abstract 101)."},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950140305"}],"container-title":["Medical and Pediatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmpo.2950170203","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mpo.2950170203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T12:58:12Z","timestamp":1697979492000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mpo.2950170203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1989,1]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1989,1]]}},"alternative-id":["10.1002\/mpo.2950170203"],"URL":"https:\/\/doi.org\/10.1002\/mpo.2950170203","archive":["Portico"],"relation":{},"ISSN":["0098-1532","1096-911X"],"issn-type":[{"value":"0098-1532","type":"print"},{"value":"1096-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1989,1]]}}}